Bioprinted three-dimensional (3D) human liver constructs provide a model for interrogating liver biology
Poster Jun 19, 2014
Justin B. Robbins, Colin M. O’Neill, Vivian Gorgen, Sharon C. Presnell, and Benjamin R. Shepherd
Conventional two dimensional (2D) cell culture models do not reflect the complexity of biological phenomena that occur in the liver microenvironment, resulting in discrepancies between in vitro predictions and in vivo realities. One of the major reasons for these differences is that primary hepatocytes, when isolated and cultured in a 2D monolayer, rapidly lose key enzymatic properties that are considered essential for predictive modeling. Loss of these key phenotypic features is one of the major limitations in toxicology screening protocols involving human hepatocytes, which has slowed the pace of development for new drug entities. In addition to challenges in maintaining differentiation, species-specific differences in hepatocellular function have also been extensively reported, making it difficult to extrapolate non-human data to the clinic. Therefore, providing better in vitro models for interrogating human liver biology will have a major impact in the fields of toxicology and hepatology. In this report, we demonstrate that 3D bioprinted liver tissue mimetics composed of parenchymal (human primary hepatocytes and hepatic cell lines) and non-parenchymal cell populations (endothelial cells [EC] and hepatic stellates) can be cultured for up to 42 days and retain key liver features and functions. The 3D liver neotissues are metabolically active for at least 42 days, producing essential liver-derived serum proteins including albumin, fibrinogen, and transferrin within the medium. Histological analysis of formalin-fixed paraffin-embedded tissues at multiple time points revealed well-organized architecture, with intercellular junctions between parenchymal cells and clear evidence of lumenized, CD31-positive, EC-lined microvascular structures. Toxicity studies by examining ATP and lactate dehydrogenase (LDH) activities of the 3D liver constructs when dosed with known hepatotoxic agents were undertaken. Exposure of the bioprinted liver tissue to acetaminophen resulted in LD50 values similar to published human in vivo values. Enhancement of the acetaminophen toxic effect was observed when combined with ethanol treatment of bioprinted neotissues. Finally, the 3D liver neotissues responded in a dose dependent manner to the small molecule diclofenac, a known hepatotoxin. Not only do 3D neotissues allow biochemical interrogation of these toxicants, they also permit physical examination of the cellular populations within the tissue by histology. These results demonstrate the potential for the bioprinted 3D liver tissues in drug discovery and development, and human disease modeling.
Psychiatric Risk Gene Cacna1c and Early Life Stress: Potential Gene-Environment interactions?Poster
Early life stress (ELS) is highly associated with development of psychopathology
and mood disorders in adulthood. Genetic studies have identified variation in the gene calcium voltage-gated channel subunit alpha1C (CACNA1C) to increase risk for several psychiatric disorders. This poster assessed the expression of Cacna1c following prepubertal stress.
Idiopathic Pulmonary Fibrosis: The Importance of Multiple-site SamplingPoster
This research project attempts to highlight the importance of sampling from multiple sites of the lungs of patients with Idiopathic Pulmonary Fibrosis. Examining the histopathology of the human lung samples with IPF shows varying levels of fibrosis in different sites of the lung. To ensure an accurate representation of a patient's lungs, it is important to obtain samples from multiple sites on the lobes of the lungs.READ MORE
Hepatocellular Carcinoma with Small Cell Histology: A Rare Mimic of Metastatic Tumors Involving the LiverPoster
Two cases of hepatocellular carcinoma (HCC) with small cell histology, a rare morphologic variant of HCC, are presented.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018